Latest Reimbursement News

Page 4 of 50
OncoSil Medical delivered sharper commercial growth and a string of regulatory milestones in FY26, but the oncology device company remains heavily loss-making and dependent on future sales or fresh capital. Revenue rose 44% to $1.68 million while operating cash outflow reached $10.47 million.
Victor Sage
Victor Sage
27 Oct 2026
Hydrix reported stronger contract momentum and launched a defence strategy in FY26, but revenue fell, cash burn increased and its statutory loss widened to $6.72 million. The auditor identified a material uncertainty over the company’s ability to continue as a going concern, despite a $5.2 million capital raising and planned debt conversions.
Sophie Babbage
Sophie Babbage
27 Oct 2026
Rhythm Biosciences has widened access to its ColoSTAT blood test, lifted quarterly revenue 64% and advanced reimbursement and NHS evaluation work. The progress sits alongside A$1.803 million in cash and an estimated 1.22 quarters of funding at the current operating burn.
Ada Torres
Ada Torres
27 Oct 2026
Altamin has completed the technical work underpinning its Lazio Scoping Study, but pushed the release to the end of Q1 2027 while reporting A$1.56 million in cash and a 1.41-quarter funding estimate. The company has drawn A$1 million from a shareholder-linked facility and is relying on further debt, grant reimbursements, a possible Gorno transaction and potential equity funding to support its plans.
Maxwell Dee
Maxwell Dee
26 Oct 2026
Maritana Minerals has moved the Black Swan Processing Hub into active construction after securing all statutory process-plant approvals. The gold developer ended September with A$214.5 million in cash, a larger resource base and first gold still targeted for the second half of 2027.
Maxwell Dee
Maxwell Dee
26 Oct 2026
FINEOS lifted its quarterly client receipts 47% and ended September with €51.7 million in cash, while maintaining FY26 revenue guidance of €147 million to €152 million. The stronger cash position was helped by the delayed collection of approximately €8 million in invoices, but no new sales were finalised during the quarter.
Victor Sage
Victor Sage
26 Oct 2026
Artrya has converted its largest US customer and first SAPPHIRE Study participant into a five-year commercial agreement, while delaying its planned Coronary Flow FDA submission to strengthen clinical evidence. The Salix rollout is gaining traction, but revenue remains early and scan volumes are undisclosed.
Victor Sage
Victor Sage
26 Oct 2026
Cochlear has reaffirmed FY27 underlying net profit guidance of $330 million to $350 million after a disappointing FY26, while pointing to strong Nexa adoption and progress on fully implantable hearing technology. The company is cutting fixed costs and expanding medical referral pathways as it seeks to convert a large pool of untreated adult hearing loss into growth.
Victor Sage
Victor Sage
26 Oct 2026
Gold Hydrogen has secured up to $2 million against its verified FY2026 R&D claim and can seek a further $4 million against FY2027 expenditure. The funding gives the explorer near-term support for well-testing analysis and commercialisation studies, but carries a 16.5% annual interest rate and security over its R&D claims.
Maxwell Dee
Maxwell Dee
23 Oct 2026
Equus Energy has secured a binding conditional 10-year gas sales agreement with Alcoa covering about 50 TJ a day, while receiving US$1.5 million to fund the next stage of project partnering. The milestone strengthens the commercial case for the Equus Gas Project, but the development remains pre-FID and requires substantial capital, partners and approvals.
Maxwell Dee
Maxwell Dee
23 Oct 2026
Arika Resources has secured up to $211,213 in Western Australian government co-funding for two 600-metre diamond holes at its Pennyweight Point prospect. The drilling will test depth extensions to known gold mineralisation and a conceptual porphyry-style gold-copper system that remains untested at depth.
Maxwell Dee
Maxwell Dee
22 Oct 2026
Phoslock Environmental Technologies Limited (ASX:PET) reduced its September-quarter operating cash outflow to A$21,000 as sales receipts more than doubled from the previous quarter. The company has paused manufacturing in China after storage capacity was reached, while new lanthanum formulations and a first Phoslock 10 field trial move forward.
Maxwell Dee
Maxwell Dee
22 Oct 2026

Browse the archive

Full archive